Thursday, August 08, 2019 6:19:54 AM
Compiled:THE U.S. FDA: 08/08/19
_______________________________________________________________________________________
5/8/19 FDA GENERAL CONSIDERATIONS FOR CLINICAL STUDIES:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150245171
FDA position-guidance on (EHR) records and tool uses. ( from nidan7500 )
https://www.fda.gov/files/drugs/published/Electronic-Technologies-in-Clinical-Trials---2.pdf
FDA In Brief:
FDA & European Medicines Agency collaborate on drug quality and manufacturing data to improve patient access to medically necessary medications 7/31/19 (from kevli33)
https://www.fda.gov/news-events/fda-brief/fda-brief-fda-european-medicines-agency-collaborate-drug-quality-and-manufacturing-data-improve
Janet Woodcock, FDA, on future innovation in drug development
Comments on the above
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149424734
Gottleib - former FDA commissioner on CNBC on what he believes is an area of HUGE potential.
Start listening at 4:00 minute mark (from Lima4918)
https://www.cnbc.com/video/2019/06/17/fmr-fda-commissioner-on-biotech-cannabis-and-the-meatless-markets.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Coming change in FDA process - the office of innovation (Office of Drug Evaluation Science) 1/8/19:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145956816
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145966349
Will Fadiran negotiate a SPA with the FDA?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149960752
FDA leaks, a time honored tradition:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830
On what planet does the FDA put the health of the people first?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140058548
The FDA, pay for play, and peer review:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141334023
3/14/19 Update from Gottlieb on changes in drug trial procedure
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147558978
New(Feb 2019) guidance highlights basis for possible early approval of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146543702
This could speed up and simplify and reduce cost of “precision enrollment” screening time:(from biostockclub)
https://neurosciencenews.com/artificial-intelligence-alzheimers-13097/
“The Future of Drug Trials Is Better Data and Continuous Monitoring” (from kevli33)
https://hbr.org/2019/05/the-future-of-drug-trials-is-better-data-and-continuous-monitoring
Alzheimer’s Disease conference, held October 24–27 2018 in Barcelona, Spain,
Which Are the Right Tests to Satisfy New FDA Guidance?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244
Changing FDA perspective toward trials and electronic data collection.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099899
How RWE data will be used and new systems will be applied. (from nidan7500)
https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RealWorldEvidence/UCM627769.pdf
Precedents and legal pathways to approval from Biostockclub & Nidan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166
New FDA accelerated approval guidance for labeling - from Nidan7500
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM390058.pdf
FDA planning new guidance, hires in cell and gene therapies for 2019 (From basparks79)
https://www.fiercebiotech.com/biotech/fda-planning-new-guidance-hires-cell-and-gene-therapies-for-2019
Link from the above post naming precedents for drug approval without a Random Controlled Trial:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932294/#!po=95.1923
New Rare Disease Draft Guidance (Feb. 2019 from nidan7500)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM629579.pdf?rel=0
Electronic Health Records to be used in FDA trials (from Rubyred77)
https://ehrintelligence.com/news/ehr-data-to-provide-real-world-evidence-for-clinical-trials
New guidance for early stage Alzheimer's being developed in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208035
What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471
Check this out on retrospective validation: (from Nidan7500)
https://www.nature.com/articles/6500363#hypothetical-safety-example-seeking-drug-approval-in-the-dnasubgroup-of-patients-with-less-risk-of-a-cardiovascular-adverse-events-after-trial-completion
4/3/19 - New position paper from FDA on AI supports Cognision partnership
(see Anavex Partners link at bottom of post for more on Cognision)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271
A 1995 paper predicts loss of U.S. credibility in drug approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145668454
Alzheimer's research receives largest ever funding boost in 2019 budget
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143880556
Are blinded, placebo trials really necessary?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147253537
Is corporate dominance of the FDA achieved by the User Fee Act (PDUFA)?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147227616
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147231843
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147234966
New programs to promote drug manufacturing innovation anounced by Gottleib(from Kevli33)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631293.htm?utm_campaign=021319_Statement_FDA%20announces%20programs%20to%20promote%20adoption%20of%20innovations%20in%20drug%20manufacturing&utm_medium=email&utm_source=Eloqua
Woodcock says the clinical trial system is broken. (From nidan7500)
https://www.biopharmadive.com/news/fdas-woodcock-the-clinical-trial-system-is-broken/542698/
Did the FDA cause the opioid crisis (from tradeherpete)
https://www.cbsnews.com/news/opioid-epidemic-did-the-fda-ignite-the-crisis-60-minutes/?ftag=MSF0951a18
On ACTC participation in the U.S.:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144487503
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208260
Why ACTC is the holdup in North American Alzheimer's trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145449081
Update on NIH/ACTC (from Talon38)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089795
Anavex, ACTC and Paul Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089981
The pace of NIH-ACTC movement is Glacial. (from Nidan7500)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147091783
CDER expediting drugs - post from 04/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148080157
Payers and Right to Try:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148132893
_______________________________________________________________________________________
5/8/19 FDA GENERAL CONSIDERATIONS FOR CLINICAL STUDIES:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150245171
FDA position-guidance on (EHR) records and tool uses. ( from nidan7500 )
https://www.fda.gov/files/drugs/published/Electronic-Technologies-in-Clinical-Trials---2.pdf
FDA In Brief:
FDA & European Medicines Agency collaborate on drug quality and manufacturing data to improve patient access to medically necessary medications 7/31/19 (from kevli33)
https://www.fda.gov/news-events/fda-brief/fda-brief-fda-european-medicines-agency-collaborate-drug-quality-and-manufacturing-data-improve
Janet Woodcock, FDA, on future innovation in drug development
Comments on the above
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149424734
Gottleib - former FDA commissioner on CNBC on what he believes is an area of HUGE potential.
Start listening at 4:00 minute mark (from Lima4918)
https://www.cnbc.com/video/2019/06/17/fmr-fda-commissioner-on-biotech-cannabis-and-the-meatless-markets.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Coming change in FDA process - the office of innovation (Office of Drug Evaluation Science) 1/8/19:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145956816
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145966349
Will Fadiran negotiate a SPA with the FDA?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149960752
FDA leaks, a time honored tradition:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830
On what planet does the FDA put the health of the people first?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140058548
The FDA, pay for play, and peer review:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141334023
3/14/19 Update from Gottlieb on changes in drug trial procedure
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147558978
New(Feb 2019) guidance highlights basis for possible early approval of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146543702
This could speed up and simplify and reduce cost of “precision enrollment” screening time:(from biostockclub)
https://neurosciencenews.com/artificial-intelligence-alzheimers-13097/
“The Future of Drug Trials Is Better Data and Continuous Monitoring” (from kevli33)
https://hbr.org/2019/05/the-future-of-drug-trials-is-better-data-and-continuous-monitoring
Alzheimer’s Disease conference, held October 24–27 2018 in Barcelona, Spain,
Which Are the Right Tests to Satisfy New FDA Guidance?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244
Changing FDA perspective toward trials and electronic data collection.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099899
How RWE data will be used and new systems will be applied. (from nidan7500)
https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RealWorldEvidence/UCM627769.pdf
Precedents and legal pathways to approval from Biostockclub & Nidan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166
New FDA accelerated approval guidance for labeling - from Nidan7500
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM390058.pdf
FDA planning new guidance, hires in cell and gene therapies for 2019 (From basparks79)
https://www.fiercebiotech.com/biotech/fda-planning-new-guidance-hires-cell-and-gene-therapies-for-2019
Link from the above post naming precedents for drug approval without a Random Controlled Trial:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932294/#!po=95.1923
New Rare Disease Draft Guidance (Feb. 2019 from nidan7500)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM629579.pdf?rel=0
Electronic Health Records to be used in FDA trials (from Rubyred77)
https://ehrintelligence.com/news/ehr-data-to-provide-real-world-evidence-for-clinical-trials
New guidance for early stage Alzheimer's being developed in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208035
What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471
Check this out on retrospective validation: (from Nidan7500)
https://www.nature.com/articles/6500363#hypothetical-safety-example-seeking-drug-approval-in-the-dnasubgroup-of-patients-with-less-risk-of-a-cardiovascular-adverse-events-after-trial-completion
4/3/19 - New position paper from FDA on AI supports Cognision partnership
(see Anavex Partners link at bottom of post for more on Cognision)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271
A 1995 paper predicts loss of U.S. credibility in drug approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145668454
Alzheimer's research receives largest ever funding boost in 2019 budget
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143880556
Are blinded, placebo trials really necessary?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147253537
Is corporate dominance of the FDA achieved by the User Fee Act (PDUFA)?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147227616
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147231843
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147234966
New programs to promote drug manufacturing innovation anounced by Gottleib(from Kevli33)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631293.htm?utm_campaign=021319_Statement_FDA%20announces%20programs%20to%20promote%20adoption%20of%20innovations%20in%20drug%20manufacturing&utm_medium=email&utm_source=Eloqua
Woodcock says the clinical trial system is broken. (From nidan7500)
https://www.biopharmadive.com/news/fdas-woodcock-the-clinical-trial-system-is-broken/542698/
Did the FDA cause the opioid crisis (from tradeherpete)
https://www.cbsnews.com/news/opioid-epidemic-did-the-fda-ignite-the-crisis-60-minutes/?ftag=MSF0951a18
On ACTC participation in the U.S.:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144487503
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208260
Why ACTC is the holdup in North American Alzheimer's trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145449081
Update on NIH/ACTC (from Talon38)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089795
Anavex, ACTC and Paul Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089981
The pace of NIH-ACTC movement is Glacial. (from Nidan7500)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147091783
CDER expediting drugs - post from 04/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148080157
Payers and Right to Try:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148132893
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM

